These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37731485)

  • 1. Immunological correlates of protection afforded by PHV02 live, attenuated recombinant vesicular stomatitis virus vector vaccine against Nipah virus disease.
    Monath TP; Nichols R; Feldmann F; Griffin A; Haddock E; Callison J; Meade-White K; Okumura A; Lovaglio J; Hanley PW; Clancy CS; Shaia C; Rida W; Fusco J
    Front Immunol; 2023; 14():1216225. PubMed ID: 37731485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential.
    Monath TP; Nichols R; Tussey L; Scappaticci K; Pullano TG; Whiteman MD; Vasilakis N; Rossi SL; Campos RK; Azar SR; Spratt HM; Seaton BL; Archambault WT; Costecalde YV; Moore EH; Hawks RJ; Fusco J
    PLoS Pathog; 2022 Jun; 18(6):e1010658. PubMed ID: 35759511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins.
    DeBuysscher BL; Scott D; Marzi A; Prescott J; Feldmann H
    Vaccine; 2014 May; 32(22):2637-44. PubMed ID: 24631094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant vesicular stomatitis virus-vectored vaccine induces long-lasting immunity against Nipah virus disease.
    Woolsey C; Borisevich V; Fears AC; Agans KN; Deer DJ; Prasad AN; O'Toole R; Foster SL; Dobias NS; Geisbert JB; Fenton KA; Cross RW; Geisbert TW
    J Clin Invest; 2023 Feb; 133(3):. PubMed ID: 36445779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Single-Injection Recombinant Vesicular Stomatitis Virus Vaccine to Protect Nonhuman Primates Against Lethal Nipah Virus Disease.
    Mire CE; Geisbert JB; Agans KN; Versteeg KM; Deer DJ; Satterfield BA; Fenton KA; Geisbert TW
    Emerg Infect Dis; 2019 Jun; 25(6):1144-1152. PubMed ID: 31107231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against lethal Nipah virus disease.
    Foster SL; Woolsey C; Borisevich V; Agans KN; Prasad AN; Deer DJ; Geisbert JB; Dobias NS; Fenton KA; Cross RW; Geisbert TW
    Proc Natl Acad Sci U S A; 2022 Mar; 119(12):e2200065119. PubMed ID: 35286211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid Protection from COVID-19 in Nonhuman Primates Vaccinated Intramuscularly but Not Intranasally with a Single Dose of a Vesicular Stomatitis Virus-Based Vaccine.
    Furuyama W; Shifflett K; Pinski AN; Griffin AJ; Feldmann F; Okumura A; Gourdine T; Jankeel A; Lovaglio J; Hanley PW; Thomas T; Clancy CS; Messaoudi I; O'Donnell KL; Marzi A
    mBio; 2022 Feb; 13(1):e0337921. PubMed ID: 35012339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single injection recombinant vesicular stomatitis virus vaccines protect ferrets against lethal Nipah virus disease.
    Mire CE; Versteeg KM; Cross RW; Agans KN; Fenton KA; Whitt MA; Geisbert TW
    Virol J; 2013 Dec; 10():353. PubMed ID: 24330654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection against henipaviruses in swine requires both, cell-mediated and humoral immune response.
    Pickering BS; Hardham JM; Smith G; Weingartl ET; Dominowski PJ; Foss DL; Mwangi D; Broder CC; Roth JA; Weingartl HM
    Vaccine; 2016 Sep; 34(40):4777-86. PubMed ID: 27544586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic treatment of Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody.
    Geisbert TW; Mire CE; Geisbert JB; Chan YP; Agans KN; Feldmann F; Fenton KA; Zhu Z; Dimitrov DS; Scott DP; Bossart KN; Feldmann H; Broder CC
    Sci Transl Med; 2014 Jun; 6(242):242ra82. PubMed ID: 24964990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant measles virus vaccine expressing the Nipah virus glycoprotein protects against lethal Nipah virus challenge.
    Yoneda M; Georges-Courbot MC; Ikeda F; Ishii M; Nagata N; Jacquot F; Raoul H; Sato H; Kai C
    PLoS One; 2013; 8(3):e58414. PubMed ID: 23516477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rhabdovirus-based vaccine platforms against henipaviruses.
    Kurup D; Wirblich C; Feldmann H; Marzi A; Schnell MJ
    J Virol; 2015 Jan; 89(1):144-54. PubMed ID: 25320306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct VSV-based Nipah virus vaccines expressing either glycoprotein G or fusion protein F provide homologous and heterologous protection in a nonhuman primate model.
    de Wit E; Feldmann F; Cronin J; Goldin K; Mercado-Hernandez R; Williamson BN; Meade-White K; Okumura A; Callison J; Weatherman S; Rosenke R; Avanzato VA; Lovaglio J; Scott DP; Marzi A; Feldmann H
    EBioMedicine; 2023 Jan; 87():104405. PubMed ID: 36508878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody responses to recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccination for Ebola virus disease across doses and continents: 5-year durability.
    Huttner A; Agnandji ST; Engler O; Hooper JW; Kwilas S; Ricks K; Clements TL; Jonsdottir HR; Nakka SS; Rothenberger S; Kremsner P; Züst R; Medaglini D; Ottenhoff T; Harandi AM; Siegrist CA; ; ;
    Clin Microbiol Infect; 2023 Dec; 29(12):1587-1594. PubMed ID: 37661067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coexpression of respiratory syncytial virus (RSV) fusion (F) protein and attachment glycoprotein (G) in a vesicular stomatitis virus (VSV) vector system provides synergistic effects against RSV infection in a cotton rat model.
    Brakel KA; Binjawadagi B; French-Kim K; Watts M; Harder O; Ma Y; Li J; Niewiesk S
    Vaccine; 2021 Nov; 39(47):6817-6828. PubMed ID: 34702618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.
    Matassov D; Marzi A; Latham T; Xu R; Ota-Setlik A; Feldmann F; Geisbert JB; Mire CE; Hamm S; Nowak B; Egan MA; Geisbert TW; Eldridge JH; Feldmann H; Clarke DK
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S443-51. PubMed ID: 26109675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge.
    Bossart KN; Rockx B; Feldmann F; Brining D; Scott D; LaCasse R; Geisbert JB; Feng YR; Chan YP; Hickey AC; Broder CC; Feldmann H; Geisbert TW
    Sci Transl Med; 2012 Aug; 4(146):146ra107. PubMed ID: 22875827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic administration of a cross-reactive mAb targeting the fusion glycoprotein of Nipah virus protects nonhuman primates.
    Zeitlin L; Cross RW; Woolsey C; West BR; Borisevich V; Agans KN; Prasad AN; Deer DJ; Stuart L; McCavitt-Malvido M; Kim DH; Pettitt J; Crowe JE; Whaley KJ; Veesler D; Dimitrov A; Abelson DM; Geisbert TW; Broder CC
    Sci Transl Med; 2024 Apr; 16(741):eadl2055. PubMed ID: 38569014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Species-specific immunogenicity and protective efficacy of a vesicular stomatitis virus-based Sudan virus vaccine: a challenge study in macaques.
    Marzi A; Fletcher P; Feldmann F; Saturday G; Hanley PW; Feldmann H
    Lancet Microbe; 2023 Mar; 4(3):e171-e178. PubMed ID: 36739878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection.
    Menicucci AR; Jankeel A; Feldmann H; Marzi A; Messaoudi I
    mBio; 2019 May; 10(3):. PubMed ID: 31138743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.